Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Company Overview - Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases [4] - The company is advancing its investigational drug, certepetide, which utilizes a novel uptake pathway to enhance the effectiveness of anti-cancer drugs targeting solid tumors [4] Financial Results Announcement - The company will report its financial results for the third quarter ended September 30, 2024, on November 12, 2024, after the market closes [1] - A conference call will be held at 4:30 p.m. Eastern time on the same day to discuss the results [1] Conference Call Participation - Interested participants must register for the conference call via a provided link and will receive an email with dial-in details [2] - To ensure a smooth experience, participants are encouraged to join the call 15 minutes early [2] Webcast Availability - A live webcast of the conference call will be available on Lisata's website and can be replayed for 12 months after the event [3] Future Expectations - The company anticipates announcing several milestones over the next 1.5 years and believes its projected capital will sustain operations into early 2026, covering expected data milestones from ongoing and planned clinical trials [4]